|Capinos Scherer, Charles|
Submitted to: Vaccine
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 12/16/2008
Publication Date: 1/9/2009
Citation: Waters, W.R., Palmer, M.V., Nonnecke, B.J., Thacker, T.C., Capinos Scherer, C.F., Estes, D.M., Hewinson, R.G., Vordermeier, H.M., Barnes, S.W., Federe, G.C., Walker, J.R., Glynne, R.J., Hsu, T., Weinrick, B., Biermann, K., Larsen, M.H., Jacobs, W.R. 2009. Efficacy and Immunogenicity of Mycobacterium bovis Delta RD1 against Aerosol M. bovis Infection in Neonatal Calves. Vaccine. 27(8):1201-1209.
Interpretive Summary: Despite highly successful eradication efforts in several countries, tuberculosis of cattle remains a serious health concern worldwide. In addition, an outbreak of tuberculosis in white-tailed deer in Michigan and continued importation of tuberculous cattle from Mexico have seriously hindered eradication efforts within the United States. Improved techniques are needed for prevention of tuberculosis in cattle. In this study, a new effective vaccine for the prevention of bovine tuberculosis is described. Knowledge obtained from this study will assist in the control of tuberculosis in cattle.
Technical Abstract: An attenuated Mycobacterium bovis RD1 knockout (Delta RD1) vaccine administered to calves at 2 weeks of age provided similar efficacy as M. bovis bacille Calmette Guerin (BCG) against low dose, aerosol challenge with virulent M. bovis at 3.5m of age. Approximately 4.5 months after challenge, both Delta RD1- and BCG-vaccinates had reduced tuberculosis (TB)-associated pathology in lungs and lung-associated lymph nodes and M. bovis colonization of tracheobronchial lymph nodes as compared to non-vaccinates. Central memory responses elicited by either Delta RD1 or BCG prior to challenge correlated with reduced pathology. Neither Delta RD1 or BCG elicited IFN-gamma responses to rESAT-6:CFP-10 prior to challenge, an emerging tool for modern TB surveillance programs. The Delta RD1 strain may prove useful for bovine TB vaccine programs, particularly if additional mutations are included to improve safety / immunogenicity.